HomeCompareGBT vs EPRT

GBT vs EPRT: Dividend Comparison 2026

GBT yields 2.92% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $39.3K in total portfolio value
10 years
GBT
GBT
● Live price
2.92%
Share price
$68.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.1K
Annual income
$352.49
Full GBT calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — GBT vs EPRT

📍 EPRT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBTEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBT + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBT pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBT
Annual income on $10K today (after 15% tax)
$248.21/yr
After 10yr DRIP, annual income (after tax)
$299.62/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $10,615.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBT + EPRT for your $10,000?

GBT: 50%EPRT: 50%
100% EPRT50/50100% GBT
Portfolio after 10yr
$43.7K
Annual income
$6,596.60/yr
Blended yield
15.08%
📊

Analyst Conviction Gap

Where Wall Street is split right now

GBT
Analyst Ratings
18
Buy
11
Hold
Consensus: Buy
Price Target
$60.38
-11.8% upside vs current
Range: $36.00 — $110.00
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBT buys
0
EPRT buys
0
No recent congressional trades found for GBT or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBTEPRT
Forward yield2.92%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$24.1K$63.4K
Annual income after 10y$352.49$12,840.73
Total dividends collected$3.2K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$60.38$35.50

Year-by-year: GBT vs EPRT ($10,000, DRIP)

YearGBT PortfolioGBT Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$10,992$292.01$11,205$505.18$213.00EPRT
2$12,061$299.98$12,672$682.46$611.00EPRT
3$13,213$307.63$14,490$930.48$1.3KEPRT
4$14,453$314.97$16,786$1,282.69$2.3KEPRT
5$15,787$321.98$19,753$1,791.56$4.0KEPRT
6$17,221$328.69$23,677$2,541.64$6.5KEPRT
7$18,761$335.08$29,008$3,672.99$10.2KEPRT
8$20,416$341.18$36,463$5,425.08$16.0KEPRT
9$22,192$346.98$47,238$8,221.57$25.0KEPRT
10$24,098$352.49$63,385$12,840.73$39.3KEPRT

GBT vs EPRT: Complete Analysis 2026

GBTStock

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Full GBT Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this GBT vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBT vs SCHDGBT vs JEPIGBT vs OGBT vs KOGBT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.